Azilsartan

Drug Profile

Azilsartan

Alternative Names: Azilva; TAK-536

Latest Information Update: 18 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Takeda
  • Developer Lees Pharmaceutical Holdings; Takeda
  • Class Antihypertensives; Benzimidazoles; Oxadiazoles; Small molecules
  • Mechanism of Action Angiotensin type 1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hypertension
  • Phase III Essential hypertension

Most Recent Events

  • 17 Aug 2017 Azilsartan market licensed to Hikma Pharmaceuticals in Middle East and North Africa
  • 11 Mar 2017 Takeda completes a phase I bioequivalence trial in Healthy volunteers in Japan (PO, Granules) (NCT03042299)
  • 04 Feb 2017 Takeda initiates enrolment in a phase I bioequivalence trial in Healthy volunteers in Japan (PO, Granules) (JapicCTI173503) (NCT03042299)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top